Unusual false‐positive case of urinary screening for buprenorphine
Authors:
- 1 January 2011
- journal article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 25 (4) , 244-245
Abstract
Buprenorphine is a centrally acting analgesic drug that is administered for the management of opioid dependence and as an analgesic drug for the treatment of chronic pain. The growing use of this substance has determined an increased need for laboratory testing for either detection and confirmation of the illicit use or monitoring compliance as a substitution therapy for opioid dependence. We describe here the case of urinary sample adulteration with exogenous buprenorphine (6,952 ng/ml), which has led to afalse‐positive immunoassay test result (14.9 ng/ml) on a subsequent sample due to a phenomenon of instrumental carry‐over. This unusual case confirms the importance to take into account adulteration when screening urines for buprenorphine in patients undergoing substitution therapy for opioid dependence, routinely perform a confirmation assay on positive samples, and rule out instrumental carry‐over. J. Clin. Lab. Anal. 25:244–245, 2011.Keywords
This publication has 3 references indexed in Scilit:
- Comparison of three commercial tests for buprenorphine screening in urineAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2007
- BuprenorphineClinical Pharmacokinetics, 2005
- Urine drug screening in the medical settingClinica Chimica Acta, 2002